Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Assets (2017 - 2025)

Aclaris Therapeutics has reported Other Non-Current Assets over the past 9 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.8 million for Q4 2025, down 9.62% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (down 9.62% YoY), and the annual figure for FY2025 was $2.8 million, down 9.62%.
  • Other Non-Current Assets for Q4 2025 was $2.8 million at Aclaris Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ACRS hit a ceiling of $4.2 million in Q4 2023 and a floor of $2.7 million in Q3 2023.
  • Median Other Non-Current Assets over the past 5 years was $3.2 million (2024), compared with a mean of $3.3 million.
  • Biggest five-year swings in Other Non-Current Assets: soared 52.2% in 2023 and later decreased 26.26% in 2024.
  • Aclaris Therapeutics' Other Non-Current Assets stood at $3.6 million in 2021, then fell by 23.13% to $2.7 million in 2022, then skyrocketed by 52.2% to $4.2 million in 2023, then decreased by 26.26% to $3.1 million in 2024, then fell by 9.62% to $2.8 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.